CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

PURPOSE: Metastatic esophagogastric cancer treatments after failure of second-line chemotherapy are limited. Nivolumab demonstrated superior overall survival (OS) versus placebo in Asian patients with advanced gastric or gastroesophageal junction cancers. We assessed the safety and efficacy of nivol...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Janjigian, Yelena Y., Bendell, Johanna, Calvo, Emiliano, Kim, Joseph W., Ascierto, Paolo A., Sharma, Padmanee, Ott, Patrick A., Peltola, Katriina, Jaeger, Dirk, Evans, Jeffry, de Braud, Filippo, Chau, Ian, Harbison, Christopher T., Dorange, Cecile, Tschaika, Marina, Le, Dung T.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2018
Soggetti:
ORIGINAL REPORTS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6161834/
https://ncbi.nlm.nih.gov/pubmed/30110194
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.76.6212
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi